Immunitybio Stock Today
| IBRX Stock | USD 2.87 0.03 1.03% |
PerformanceWeak
| Odds Of DistressLow
|
Immunitybio is trading at 2.87 as of the 17th of March 2025; that is 1.03 percent decrease since the beginning of the trading day. The stock's open price was 2.9. Immunitybio has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. The company has 853.44 M outstanding shares of which 56.96 M shares are currently shorted by private and institutional investors with about 9.95 trading days to cover. More on Immunitybio
Moving together with Immunitybio Stock
| 0.78 | DMAC | DiaMedica Therapeutics Earnings Call Today | PairCorr |
Moving against Immunitybio Stock
Immunitybio Stock Highlights
| CEO President | Richard Adcock |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Immunitybio (IBRX) is traded on NASDAQ Exchange in USA. It is located in 3530 John Hopkins Court, San Diego, CA, United States, 92121 and employs 680 people. Immunitybio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.45 B. Immunitybio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 853.44 M outstanding shares of which 56.96 M shares are currently shorted by private and institutional investors with about 9.95 trading days to cover.
Immunitybio currently holds about 82.94 M in cash with (391.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21.
Check Immunitybio Probability Of Bankruptcy
Ownership AllocationImmunitybio has a total of 853.44 Million outstanding shares. Immunitybio retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 62.9 (percent) of Immunitybio outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immunitybio Ownership Details
Immunitybio Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Immunitybio market risk premium is the additional return an investor will receive from holding Immunitybio long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0391 | |||
| Jensen Alpha | 0.3085 | |||
| Total Risk Alpha | 1.01 | |||
| Sortino Ratio | 0.0637 |
Immunitybio Stock Against Markets
Immunitybio Corporate Management
| Jason JD | General Secretary | Profile | |
| Sandeep MD | Chief Officer | Profile | |
| Helen Luu | Chief Officer | Profile | |
| Leonard MD | Chief Officer | Profile | |
| Jason Liljestrom | General Secretary | Profile | |
| Bruce MD | Senior Affairs | Profile |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.